Observation of the effectiveness of whole course of comprehensive nursing in clinical care after the surgery for benign prostatic hyperplasia

This study discussed the effect of whole course of comprehensive nursing after the operation for benign prostatic hyperplasia (BPH). Eighty-six patients with BPH who were to undergo prostatic hyperplasia surgery were divided into a control group and a study group based on therapeutic method. 43 patients in each group were postoperatively given usual care in the control group and comprehensive nursing in the study group. The mental status, prostate symptoms, quality of life, complications and degree of satisfaction were compared before and after the interventions. The mental status, prostate symptoms, and quality of life (QOL) of the patients were relatively similar (p > 0.05) before the intervention. The scores of self-rating anxiety scale (SAS), self-rating depression scale (SDS), international prostate symptom scale (IPSS) and QOL of patients in the study group were significantly lower than those in the control group after the intervention (p < 0.05). The incidence of complications in the study group was 4.65%, which was significantly lower than that of the control group at 18.60% (p < 0.05), while the satisfaction rate in the study group was 95.35%, which was significantly higher than that of the control group at 69.77% (p < 0.05) . The whole course of comprehensive nursing after the operation for BPH surgery was effective in improving patients’ mental status, promoting the recovery of prostate, improving patients’ quality of life, reducing the incidence of complications, and improving patients’ satisfaction.

Benign prostatic hyperplasia; Usual care; Comprehensive nursing; Nursing efficacy; Satisfaction

[1] Langan RC. Benign prostatic hyperplasia. Primary Care. 2019; 46: 223–232.

[2] Madersbacher S, Sampson N, Culig Z. Pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement: a mini-review. Gerontology. 2019; 65: 458–464.

[3] Foo KT. What is a disease? what is the disease clinical benign prostatic hyperplasia (BPH)? World Journal of Urology. 2019; 37: 1293–1296.

[4] Rastrelli G, Vignozzi L, Corona G, Maggi M. Testosterone and benign prostatic hyperplasia. Sexual Medicine Reviews. 2019; 7: 259–271.

[5] Lerner LB, McVary KT, Barry MJ, Bixler BR, Dahm P, Das AK, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA GUIDELINE PART I-initial work-up and medical management. The Journal of Urology. 2021; 206; 806–817.

[6] Dornbier R, Pahouja G, Branch J, McVary KT. The new American urological association benign prostatic hyperplasia clinical guidelines: 2019 update. Current Urology Reports. 2020; 21: 32.

[7] Miernik A, Gratzke C. Current treatment for benign prostatic hyperplasia. German International Journal of Medicine. 2020; 117: 843–854.

[8] Wang Z, Zhang J, Zhang H, Liu S, Sun D, Hu L, et al. Impact on sexual function of plasma button transurethral vapour enucleation versus plasmakinetic resection of the large prostate >90 mL: results of a prospective, randomized trial. Andrologia. 2020; 52: e13390.

[9] Zheng Z, Wu Z, Li K, Zhu Q, Li H, Liu X, et al. Incidence and risk factors of venous thromboembolism in patients after transurethral resection of the prostate (TURP). Frontiers in Surgery. 2021; 8: 744244.

[10] Li S, Sun Y, Liu J, Han F, Liu B, Liu W. Nursing research on benign prostatic hyperplasia based on continuous nursing care. Computational and Mathematical Methods in Medicine. 2022; 2022: 1–7.

[11] Jung JH, Shin TY, Mccutcheon KA, Borofsky M, Narayan V, Young S, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Cochrane Database of Systematic Reviews. 2017; 2017: CD012867.

[12] Oelke M, Gravas S. Relevance of benign prostatic hyperplasia and associated conditions for urologists, health care systems, and society. World Journal of Urology. 2010; 28: 1–2.

[13] Unnikrishnan R, Almassi N, Fareed K. Benign prostatic hyperplasia: evaluation and medical management in primary care. Cleveland Clinic Journal of Medicine. 2017; 84: 53–64.

[14] Wang K, Chen M, Liu Y, Xiao W, Qian Y, Liu X. Efficacy and safety of prostatic artery embolization in the treatment of high risk benign prostatic hyperplasia and its influence on postoperative life quality of patients. Frontiers in Surgery. 2022; 9: 905394.

[15] Cheng NZ, Tang ZY, Liu Y, Liu XS, Qi L. Effect of transurethral resection of prostate on quality of life in aged patients with benign prostatic hyperplasia. Journal of Central South University. 2008; 33: 975–978. (In Chinese)

[16] Zhou ZX, Chen HB, Liu W, Xu GS, Zhang YD, Peng XZ, et al. Prostatic artery embolization for high-risk patients with benign prostatic hyperplasia: A clinical effect observation. National Journal of Andrology. 2021; 27: 226–230. (In Chinese)

[17] Niu C, Huang X, Wang L, Liu F. Effect of hospital, community and home care model on nursing and quality of life of patients after transurethral resection of benign prostatic hyperplasia. American Journal of Translational Research. 2021; 13: 4959–4968.

[18] Robert G, De La Taille A, Descazeaud A. Epidemiology of benign prostatic hyperplasia. ProgrÈS En Urologie. 2018; 28: 803–812. (In French)

[19] Egan KB. The epidemiology of benign prostatic hyperplasia associated with lower urinary tract symptoms. Urologic Clinics of North America. 2016; 43: 289–297.

[20] Tsunemori H, Sugimoto M. Effects of inflammatory prostatitis on the development and progression of benign prostatic hyperplasia: a literature review. International Journal of Urology. 2021; 28: 1086–1092.

[21] GBD 2019 Benign Prostatic Hyperplasia Collaborators. The global, regional, and national burden of benign prostatic hyperplasia in 204 countries and territories from 2000 to 2019: a systematic analysis for the global burden of disease study 2019. The Lancet Healthy Longev. 2022; 3: e754–e776.

[22] Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. The Journal of Urology. 2009; 182: S27–S31.

[23] Ye Z, Huang J, Zhou L, Chen S, Wang Z, Ma L, et al. Efficacy and safety of serenoa repens extract among patients with benign prostatic hyperplasia in china: a multicenter, randomized, double-blind, placebo-controlled trial. Urology. 2019; 129: 172–179.

[24] Cicero AFG, Allkanjari O, Busetto GM, Cai T, Larganà G, Magri V, et al. Nutraceutical treatment and prevention of benign prostatic hyperplasia and prostate cancer. Italian Archives of Urology and Andrology. 2019; 91: 139–152.

[25] Knight L, Peirce S, Morris R. The PLASMA system for transurethral resection of the prostate: a NICE medical technologies guidance update. Applied Health Economics and Health Policy. 2021; 19: 665–672.

[26] Liu C, Zheng S, Li H, Xu K. Transurethral enucleation and resection of prostate in patients with benign prostatic hyperplasia by plasma kinetics. The Journal of Urology. 2010; 184: 2440–2445.

[27] Giulianelli R, Gentile BC, Mirabile G, Tema G, Albanesi L, Tariciotti P, et al. Bipolar plasma enucleation of the prostate vs. open prostatectomy in large benign prostatic hyperplasia: a single centre 3-year comparison. Prostate Cancer and Prostatic Diseases. 2019; 22: 110–116.

[28] Gan Y, Deng L, He Q, Li C, He L, Long Z. Immediate transurethral plasma kinetic enucleation of the prostate gland for treatment of benign prostatic hyperplasia-associated massive hemorrhage: a single-center experience. Frontiers in Surgery. 2021; 8: 810175.

[29] Ren X, Jin J, Chen Y, Jin J. Research on the effect of nursing methods for gestational diabetes mellitus based on comprehensive nursing intervention. Computational and Mathematical Methods in Medicine. 2022; 2022: 1–10.

[30] Oner B, Zengul FD, Oner N, Ivankova NV, Karadag A, Patrician PA. Nursing-sensitive indicators for nursing care: a systematic review (1997–2017). Nursing Open. 2021; 8: 1005–1022.